**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 55794

**Manuscript Type:** OPINION REVIEW

**role of betaine in liver disease-worth revisiting or has the die been cast?**

Mukherjee S. Betaine liver disease

Sandeep Mukherjee

**Sandeep Mukherjee,** Department of Medicine, Creighton University Medical Center, Division of Gastroenterology, Omaha, NE 68124, United States

**Author contributions:** Mukherjee S wrote this manuscript.

**Corresponding author: Sandeep Mukherjee, FRCP (C), MBChB, Full Professor,** Department of Medicine, Creighton University Medical Center, Division of Gastroenterology, Education Building, Suite 401 7710 Mercy Road, Omaha, NE 68124, United States. sandeep.mukherjee@alegent.org

**Received:** May 21, 2020

**Revised:** August 25, 2020

**Accepted:** September 16, 2020

**Published online:** October 14, 2020

**Abstract**

Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries due to the epidemic of obesity and insulin resistance. Unfortunately, no medication is approved for NASH and risk factor modification is often advised. Over the last decade, several clinical trials on NASH have been conducted with several ongoing and the future looks promising. Although betaine (trimethyl glycine) was evaluated for NASH, results were mixed in the clinical trials in large part due to the quality of the studies. It seems reasonable to re-evaluate betaine in clinical trials for NASH and alcoholic liver disease due to its low cost, tolerability and mechanism of action.

**Key Words:** Betaine; Obesity; Insulin resistance; Nonalcoholic steatohepatitis; Cirrhosis; S-adenosyl homocysteine; S-adenosyl methionine

Mukherjee S. role of betaine in liver disease-worth revisiting or has the die been cast? *World J Gastroenterol* 2020; 26(38): 5745-5748

URL: https://www.wjgnet.com/1007-9327/full/v26/i38/5745.htm

DOI: https://dx.doi.org/10.3748/wjg.v26.i38.5745

**Core Tip:** This article revisits the role of betaine in liver disease with a focus on nonalcoholic steatohepatitis. Although a randomized controlled trial did not report benefit over placebo, there were limitations with the study. Given the excellent safety profile and tolerance of betaine, it appears this would be an appropriate time to re-evaluate betaine for liver diseases such as nonalcoholic and alcoholic liver diseases.

**INTRODUCTION**

Betaine (or trimethy glycine) is a naturally occurring dietary compound which appears to have a beneficial effect in studies on both alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH). It is also synthesized in the liver by the oxidation of dietary choline and common causes of betaine deficiency are often related to malnutrition from conditions such as chronic alcoholism[1]. Although the mechanisms of its actions are complex, betaine is believed to reverse inflammation, hepatic steatosis and fibrosis by several mechanisms: (1) Acting as a methyl donor for the conversion of homocysteine to methionine during alcohol exposure or in the presence of vitamin B12 and folate deficiency, all of which inhibit methionine synthetase activity; (2) Methylating phosphatidylethanolamine to phosphatidylcholine *via* the Kennedy pathway (an important route in the synthesis of very low density lipoproteins prior to hepatic export); and (3) Restoration of hepatic mitochondrial glutathione and S-adenosyl methionine (SAM): S-adenosyl homocysteine ratios which reduce hepatic oxidative stress and reverse inflammation, hepatic steatosis and fibrosis in experimental and clinical studies[2,3]. As one of betaine’s principal actions is to act as a methyl donor, a diet which may be rich in carbohydrates but deficient in choline or betaine will lead to hypomethylation of homocysteine and phosphatidylethanolamine resulting in hepatic steatosis and inflammation. This was demonstrated in an elegant case-control study in which betaine levels were significantly decreased in NASH patients in contrast to patients with nonalcoholic fatty liver disease (NAFLD)[4]. In addition, mutations in mitochondrial dimethyglycine dehydrogenase, an enzyme involved in choline metabolism, were significantly associated with patients who had more advanced liver disease.

Despite these encouraging findings in multiple pre-clinical studies, betaine has not been extensively investigated in large randomized studies for the treatment of nonalcoholic or alcoholic liver disease. Since 2000, only four clinical trials have evaluated betaine for the treatment or NASH but due to limitations with study design, definitive conclusions on the impact of betaine on NASH should not be made (Table 1). For example, the first study by Miglio *et al*[5] did not use histopathology to diagnose NASH and thus no conclusions could be made. The second small case series of ten patients by Abdelmalek *et al*[6] reported biochemical and histological improvement although three patients did not complete the study. This led to a larger, randomized placebo-controlled trial by the same investigator in which 35 patients were randomized to 20 g of anhydrous betaine *vs* placebo for 1 year[7]. The primary aim of the study was to assess the impact of betaine on liver function tests and the secondary aim was to determine its effect on hepatic histology according to the Brunt criteria. The investigators reported betaine had no impact on aminotransferases and in addition, no change in hepatic fibrosis was noted during the study. Fewer betaine-exposed patients *vs* placebo had an improvement in steatosis by more than 1 point (29% *vs* 61%, *P* < 0.01).Although these findings were disappointing, there were several limitations in this study, most salient of which was the high drop-out rate which was attributed to side effects. Interestingly, betaine is now available in both anhydrous form (administered in a solution) or capsules and administration of either a lower dose of betaine anhydrous or capsules may have reduced side effects and improved compliance. This study was also only one year in duration and it would seem unlikely that reversing or improving histology in a disease with an insidious onset and which takes years to develop would occur during such a short space of time. This is now reflected by the current state of clinical trials in NASH which are now several years in duration. The most recent study of betaine in NASH was a case series of 35 patients with histologically confirmed NASH of whom the majority of patients showed stability of disease progression or improvement in hepatic histology after one year of treatment[8]. However, this study was limited by the absence of a control arm.

A prospective, unblinded randomized study of betaine is currently in progress in diabetic and non-diabetic patients with a clinical diagnosis of NAFLD (based on risk factors such as obesity and insulin resistance and the exclusion of other liver diseases) and raised liver tests[9].In this 24-wk study, patients will be prescribed 4 g of betaine per day and after 4 wk will be randomized to either continue the same dose or increase to 8 g per day with the primary aim being comparing liver tests at weeks 12 compared to baseline using the paired *t* test. However, potential foreseeable limitations of this study include lack of histological confirmation or use of non-invasive markers of steatosis or fibrosis which have gained popularity in recent clinical trials as an effective substitute for liver biopsies. The duration of this study may also be of insufficient duration to determine any impact of betaine on the primary outcome. Finally, it remains unclear what the ideal dose of oral betaine should be for clinical trials in fatty liver disease as discussed above as previous studies have used significantly larger doses. It therefore remains unclear if the study findings will change management of this disease due to limitations in study design but simply add to the literature/on without any meaningful impact.

Although several studies of betaine have been performed in pre-clinical (animal) studies, only SAM has been evaluated in patients with alcoholic liver disease[10,11]. In the first randomized, double-blind, placebo-controlled study, SAM improved survival and/or delayed listing for liver transplantation in 123 patients with alcoholic cirrhosis[12]**.** This may have been due to elevated levels of hepatic glutathione, an important antioxidant derived from homocysteine metabolism, which neutralizes free radicals and prevents cell injury. Elevated glutathione levels were also was reported in a second study of SAM in patient with alcoholic liver disease[13].

Although ASH and NASH are two different diseases, they share many features which include but are not limited to hepatic steatosis, mitochondrial dysfunction, endoplasmic reticular stress, gene dysregulation in lipid metabolism and excess proinflammatory cytokines[14]. Several of these functional and histological abnormalities are ameliorated with betaine supplementation in animal studies. For example, in well-established animal models of NAFLD, betaine supplementation attenuates the high-fat, diet-induced stress response in adipose tissue and improves both insulin sensitivity and adipokine synthesis as demonstrated by activation of hepatic adenosine monophosphate-activated protein kinase and inhibition of *de novo* lipogenesis[15]. In alcoholic liver disease where methionine synthetase activity is depressed, methionine and SAM levels are maintained by betaine supplementation which is activated by homocysteine in the presence of betaine homocysteine methionine methytransferase. An additional mechanism for betaine’s protective effects in alcoholic liver disease may be due to nicotinamide adenine nucleotide synthesis by the methylation of norepinephrine to epinephrine by phenylethanolamine N methyl transferase. Although this study has not been performed in human subjects, the author suggested supplementing alcoholic beverages with betaine may prevent alcoholic liver disease[16].

**CONCLUSION**

The interest in betaine supplementation for ASH and NASH continues to evolve and should be re-evaluated in well-designed studies. Betaine has many properties that render it ideal for clinical trials for both of these conditions which are prevalent in both developed and developing countries where cost is a factor-betaine is naturally occurring, well tolerated and inexpensive. The plethora of clinical trials on NASH should not diminish the potential value of betaine which requires re-evaluation in a large, well-designed randomized trial of adequate duration. However, NASH is also prevalent in patients with human immune deficiency virus (HIV) disease who appear to have more aggressive disease than non-HIV positive patients but are often excluded from clinical trials due to their HIV status or concerns with drug interactions[17]. Betaine should be evaluated in this population of vulnerable patients and in those with alcoholic liver disease in whom histological improvement has even described after liver transplantation[18].

**REFERENCES**

1 **Craig SA**. Betaine in human nutrition. *Am J Clin Nutr* 2004; **80**: 539-549 [PMID: 15321791 DOI: 10.1093/ajcn/80.3.539]

2 **Purohit V**, Abdelmalek MF, Barve S, Benevenga NJ, Halsted CH, Kaplowitz N, Kharbanda KK, Liu QY, Lu SC, McClain CJ, Swanson C, Zakhari S. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. *Am J Clin Nutr* 2007; **86**: 14-24 [PMID: 17616758 DOI: 10.1093/ajcn/86.1.14]

3 **Day CR**, Kempson SA. Betaine chemistry, roles, and potential use in liver disease. *Biochim Biophys Acta* 2016; **1860**: 1098-1106 [PMID: 26850693 DOI: 10.1016/j.bbagen.2016.02.001]

4 **Sookoian S**, Puri P, Castaño GO, Scian R, Mirshahi F, Sanyal AJ, Pirola CJ. Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. *Liver Int* 2017; **37**: 611-619 [PMID: 27614103 DOI: 10.1111/liv.13249]

5 **Miglio F,** Rovati LC, Santoro A, Stenikar I. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. In: Efficacy and safety of oral betaine gluconate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical trial. *Arznemittelforschung* 2000; **50**: 722-727 Available from: <https://www.ncbi.nlm.nih.gov/books/NBK548774>

6 **Abdelmalek MF**, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. *Am J Gastroenterol* 2001; **96**: 2711-2717 [PMID: 11569700 DOI: 10.1111/j.1572-0241.2001.04129.x]

7 **Abdelmalek MF**, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KD. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. *Hepatology* 2009; **50**: 1818-1826 [PMID: 19824078 DOI: 10.1002/hep.23239]

8 **Mukherjee S,** Bernard T, Kharbanda K, Barak AJ, Sorrell MF, Tuma DJ. Impact of Betaine on Hepatic Fibrosis and Homocysteine in Nonalcoholic Steatohepatitis - A Prospective, Cohort Study. *The Open Translational Medicine Journal* 2011; **3**: 1-4 [DOI: 10.2174/1876399501103010001]

9 **U.S. National Library of Medicine.** A Prospective**,** Randomized, Open Label Trial of Two Doses of Oral Betaine. 2020. Available from: <https://clinicaltrials.gov/ct2/show/NCT03073343>

10 **Yang W**, Huang L, Gao J, Wen S, Tai Y, Chen M, Huang Z, Liu R, Tang C, Li J. Betaine attenuates chronic alcohol-induced fatty liver by broadly regulating hepatic lipid metabolism. *Mol Med Rep* 2017; **16**: 5225-5234 [PMID: 28849079 DOI: 10.3892/mmr.2017.7295]

11 **Varatharajalu R**, Garige M, Leckey LC, Arellanes-Robledo J, Reyes-Gordillo K, Shah R, Lakshman MR. Adverse signaling of scavenger receptor class B1 and PGC1s in alcoholic hepatosteatosis and steatohepatitis and protection by betaine in rat. *Am J Pathol* 2014; **184**: 2035-2044 [PMID: 24814604 DOI: 10.1016/j.ajpath.2014.03.005]

12 **Mato JM**, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. *J Hepatol* 1999; **30**: 1081-1089 [PMID: 10406187 DOI: 10.1016/s0168-8278(99)80263-3]

13 **Vendemiale G**, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, Carrieri V, Albano O. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. *Scand J Gastroenterol* 1989; **24**: 407-415 [PMID: 2781235 DOI: 10.3109/00365528909093067]

14 **Veskovic M**, Mladenovic D, Milenkovic M, Tosic J, Borozan S, Gopcevic K, Labudovic-Borovic M, Dragutinovic V, Vucevic D, Jorgacevic B, Isakovic A, Trajkovic V, Radosavljevic T. Betaine modulates oxidative stress, inflammation, apoptosis, autophagy, and Akt/mTOR signaling in methionine-choline deficiency-induced fatty liver disease. *Eur J Pharmacol* 2019; **848**: 39-48 [PMID: 30689995 DOI: 10.1016/j.ejphar.2019.01.043]

15 **Wang Z**, Yao T, Pini M, Zhou Z, Fantuzzi G, Song Z. Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. *Am J Physiol Gastrointest Liver Physiol* 2010; **298**: G634-G642 [PMID: 20203061 DOI: 10.1152/ajpgi.00249.2009]

16 **French SW**. How to prevent alcoholic liver disease. *Exp Mol Pathol* 2015; **98**: 304-307 [PMID: 25758202 DOI: 10.1016/j.yexmp.2015.03.007]

17 **Papagianni M**, Tziomalos K. Non-Alcoholic Fatty Liver Disease in Patients with HIV Infection *AIDS Rev* 2018; **20**: 171-173 [PMID: 30264828 DOI: 10.24875/AIDSRev.18000008]

18 **Samara K**, Liu C, Soldevila-Pico C, Nelson DR, Abdelmalek MF. Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. *Dig Dis Sci* 2006; **51**: 1226-1229 [PMID: 16944015 DOI: 10.1007/s10620-006-8038-3]

**Footnotes**

**Conflict-of-interest statement:** The author reports grants from Intercept pharmaceuticals, grants from Allergan pharmaceuticals, grants from Enanta pharmaceuticals, outside the submitted work.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** American Gastroenterological Association, No. 176328; and American Association for the Study of Liver Diseases, No. 104729.

**Peer-review started:** May 21, 2020

**First decision:** May 29, 2020

**Article in press:** September 16, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Arslan N **S-Editor:** Huang P **L-Editor:** A **P-Editor:** Ma YJ

**Table 1 Clinical trials of betaine for nonalcoholic steatohepatitis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Patients (*n*)** | **Study design** | **Study duration** | **Pre- and post-treatment biopsies** | **Results** |
| Miglio *et al*[5] | 191 | Double-blind, randomized, placebo-controlled. | 8 wk | No biopsies | Improvement in liver test with betaine |
| Abdelmalek *et al*[6] | 10 | Polit, single-arm. | 1 yr | Yes | Improvement in histology (3 did not complete study) |
| Abdelmalek *et al*[7] | 35 | Randomized, placebo-controlled. | 1 yr | Yes | No biochemical or histological improvement but high drop-out rate |
| Mukherjee *et al*[8] | 35 | Prospective, single-arm cohort. | 1 yr | Yes | Improvement in fibrosis in 62.9% |